Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzheimer's Disease Patients Receiving Donepezil Treatment

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzheimer's Disease Patients Receiving Donepezil Treatment

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donepezil (Primary) ; MK-1942 (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Adverse reactions
  • Acronyms DDI; MK-1942-005
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 24 May 2022 Status changed from active, no longer recruiting to completed.
  • 16 May 2022 Planned End Date changed from 12 Jul 2022 to 18 May 2022.
  • 16 May 2022 Planned primary completion date changed from 12 Jul 2022 to 18 May 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top